First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung CancerWU, Jenn-Yu; YU, Chong-Jen; YANG, Pan-Chyr et al.American journal of respiratory and critical care medicine. 2008, Vol 178, Num 8, pp 847-853, issn 1073-449X, 7 p.Article

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutationsWU, Jenn-Yu; WU, Shang-Gin; YANG, Chih-Hsin et al.Lung cancer. 2011, Vol 72, Num 2, pp 205-212, issn 0169-5002, 8 p.Article

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non―Small Cell Lung CancerWU, Jenn-Yu; YU, Chong-Jen; CHANG, Yeun-Chung et al.Clinical cancer research (Print). 2011, Vol 17, Num 11, pp 3812-3821, issn 1078-0432, 10 p.Article

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancerWU, Jenn-Yu; SHIH, Jin-Yuan; YANG, Chih-Hsin et al.International journal of cancer (Print). 2010, Vol 126, Num 1, pp 247-255, issn 0020-7136, 9 p.Article

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment ResponseWU, Jenn-Yu; WU, Shang-Gin; YANG, Chih-Hsin et al.Clinical cancer research (Print). 2008, Vol 14, Num 15, pp 4877-4882, issn 1078-0432, 6 p.Article

Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosisWU, Shang-Gin; HU, Fu-Chang; CHANG, Yih-Leong et al.The European respiratory journal. 2013, Vol 41, Num 2, pp 417-424, issn 0903-1936, 8 p.Article

Clinical Outcomes in Non―Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFRCHUNG, Kuei-Pin; WU, Shang-Gin; WU, Jenn-Yu et al.Clinical cancer research (Print). 2012, Vol 18, Num 12, pp 3470-3477, issn 1078-0432, 8 p.Article

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancerWU, Jenn-Yu; YU, Chong-Jen; SHIH, Jin-Yuan et al.Lung cancer. 2010, Vol 67, Num 3, pp 348-354, issn 0169-5002, 7 p.Article